SCHEMBL4374749

SCHEMBL4374749

CCNc1nc(/C=C/c2ccc([N+](=O)[O-])o2)nc2cc(F)c(N3CCN(C)CC3)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 6/20 0.38
NPC1 O15118 5/20 0.38
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
HTT P42858 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 3/20 0.38
ALDH1A1 P00352 6/20 0.38
NPSR1 Q6W5P4 3/20 0.38
POLB P06746 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
HSP90AA1 P07900 1/20 0.38
CYP3A4 P08684 1/20 0.38
GAA P10253 1/20 0.36
MITF O75030 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4883909 1.00 MAPT (0.40) MAPTKDM4ELMNANPC1KMT2A
SCHEMBL4369469 0.89 MAPT (0.40) MAPTLMNANPC1KMT2AMEN1
SCHEMBL4369466 0.89 MAPT (0.40) MAPTLMNANPC1KMT2AMEN1
SCHEMBL4879167 0.88 EHMT2 (0.42) MAPTKDM4ELMNANPC1KMT2A
SCHEMBL4879152 0.88 EHMT2 (0.42) MAPTKDM4ELMNANPC1KMT2A
SCHEMBL4887139 0.86 ALDH1A1 (0.40) MAPTKDM4ELMNANPC1KMT2A
SCHEMBL4887131 0.86 ALDH1A1 (0.40) MAPTKDM4ELMNANPC1KMT2A
SCHEMBL4882703 0.86 MAPT (0.43) MAPTKDM4ELMNANPC1KMT2A
SCHEMBL4365985 0.86 MAPT (0.43) MAPTKDM4ELMNANPC1KMT2A
SCHEMBL4885754 0.86 FLT3 (0.41) MAPTKDM4ELMNANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009046536-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) 2009-04-16 WO disclosed
WO-2009046536-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) 2009-04-16 WO disclosed
US-20080146562-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS ULYSSES PHARMACEUTICAL PRODUCTS INC., 2008-06-19 US disclosed
US-20080146562-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS ULYSSES PHARMACEUTICAL PRODUCTS INC., 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146562-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS HRH3, HRH1, NQO2 MAPT 4864/4885KDM4E 3381/4885LMNA 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.